Trials / Withdrawn
WithdrawnNCT04341935
Effects of DPP4 Inhibition on COVID-19
Effects of DPP4 Inhibition on COVID-19 Patients With Type 2 Diabetes
- Status
- Withdrawn
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 0 (actual)
- Sponsor
- University of Miami · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this research is to see if the DPP4 inhibitor linagliptin, an oral medication commonly used to treat type 2 diabetes,can help with diabetes control and reduce the severity of the COVID-19 infection
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Linagliptin | 5 mg Linagliptin administered by mouth once daily |
| DRUG | Insulin regimen | Standard of care insulin regimen as per hospital protocol |
Timeline
- Start date
- 2021-06-30
- Primary completion
- 2021-12-30
- Completion
- 2021-12-30
- First posted
- 2020-04-10
- Last updated
- 2021-06-10
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT04341935. Inclusion in this directory is not an endorsement.